Sandoz Group (SDZ) Aperçu de l'action
Sandoz Group AG développe, fabrique et commercialise des produits pharmaceutiques génériques et des biosimilaires dans le monde entier. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 3/6 |
| Croissance future | 3/6 |
| Performances passées | 2/6 |
| Santé financière | 6/6 |
| Dividendes | 2/6 |
Récompenses
Analyse des risques
Aucun risque n'a été détecté pour SDZ à partir de nos contrôles de risques.
SDZ Community Fair Values
Create NarrativeSee what 53 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Sandoz Group AG Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | CHF 65.74 |
| Plus haut sur 52 semaines | CHF 74.72 |
| Plus bas sur 52 semaines | CHF 43.86 |
| Bêta | 0.50 |
| Variation sur 1 mois | -3.21% |
| Variation sur 3 mois | -1.23% |
| Variation sur 1 an | 43.66% |
| Variation sur 3 ans | n/a |
| Variation sur 5 ans | n/a |
| Évolution depuis l'introduction en bourse | 169.98% |
Nouvelles et mises à jour récentes
Mise à jour du récit • Jul 10
SDZ: Elevated Biosimilar Ambitions Will Face Fragile Earnings And Multiple Compression Risk
Analysts have nudged their price expectations higher for Sandoz Group, with the updated fair value estimate moving from about CHF 47.30 to roughly CHF 54.20, as they adjust assumptions around revenue growth, profit margins and the stock's future P/E in light of recent mixed target changes and an upgrade in Street research. Analyst Commentary Street research on Sandoz Group has been mixed, with some firms lifting their targets and others trimming expectations.
Mise à jour du récit • Jun 26
SDZ: Mixed Rating Shifts And Biosimilar Hub Investments Will Shape Future P/E
The analyst price target for Sandoz Group has been revised to CHF 70.74, reflecting updated views on fair value, revenue growth, profit margins, and future P/E after a mix of recent target cuts, target hikes, and an upgrade from major banks. Analyst Commentary Recent Street research on Sandoz Group shows a mix of optimism and restraint, with major banks adjusting their views on valuation, execution, and growth expectations.Article d’analyse • Jun 19
Sandoz Group (SWX:SDZ) Stock Could Be 2% Overvalued After Ljubljana Biosimilar Centre Launch
Sandoz Group (SWX:SDZ) has opened a new biosimilar development centre in Ljubljana, Slovenia, a fully digitally integrated US$99 million facility that expands its in house capabilities across drug substance and drug product development. See our latest analysis for Sandoz Group. Set against this investment in Ljubljana, Sandoz Group’s 1 day share price return declined 1.60% to CHF67.68, while its year to date share price return of 18.28% and 1 year total shareholder return of 57.12% suggest...Mise à jour du récit • Jun 11
SDZ: Elevated Biosimilar Ambitions Will Face Tighter Execution And Margin Scrutiny
Analysts have lifted their CHF price target on Sandoz Group to reflect a fair value shift from about CHF 45.23 to roughly CHF 47.30, citing updated assumptions on revenue growth, margins, and future P/E expectations shaped by recent upgrades, downgrades, and target changes across the Street. Analyst Commentary Recent Street research on Sandoz Group has been mixed, with some firms expressing confidence through upgrades and higher price targets, while others are more cautious.Recent updates
Mise à jour du récit • Jul 10
SDZ: Elevated Biosimilar Ambitions Will Face Fragile Earnings And Multiple Compression Risk
Analysts have nudged their price expectations higher for Sandoz Group, with the updated fair value estimate moving from about CHF 47.30 to roughly CHF 54.20, as they adjust assumptions around revenue growth, profit margins and the stock's future P/E in light of recent mixed target changes and an upgrade in Street research. Analyst Commentary Street research on Sandoz Group has been mixed, with some firms lifting their targets and others trimming expectations.Mise à jour du récit • Jun 26
SDZ: Mixed Rating Shifts And Biosimilar Hub Investments Will Shape Future P/E
The analyst price target for Sandoz Group has been revised to CHF 70.74, reflecting updated views on fair value, revenue growth, profit margins, and future P/E after a mix of recent target cuts, target hikes, and an upgrade from major banks. Analyst Commentary Recent Street research on Sandoz Group shows a mix of optimism and restraint, with major banks adjusting their views on valuation, execution, and growth expectations.Article d’analyse • Jun 19
Sandoz Group (SWX:SDZ) Stock Could Be 2% Overvalued After Ljubljana Biosimilar Centre Launch
Sandoz Group (SWX:SDZ) has opened a new biosimilar development centre in Ljubljana, Slovenia, a fully digitally integrated US$99 million facility that expands its in house capabilities across drug substance and drug product development. See our latest analysis for Sandoz Group. Set against this investment in Ljubljana, Sandoz Group’s 1 day share price return declined 1.60% to CHF67.68, while its year to date share price return of 18.28% and 1 year total shareholder return of 57.12% suggest...Mise à jour du récit • Jun 11
SDZ: Elevated Biosimilar Ambitions Will Face Tighter Execution And Margin Scrutiny
Analysts have lifted their CHF price target on Sandoz Group to reflect a fair value shift from about CHF 45.23 to roughly CHF 47.30, citing updated assumptions on revenue growth, margins, and future P/E expectations shaped by recent upgrades, downgrades, and target changes across the Street. Analyst Commentary Recent Street research on Sandoz Group has been mixed, with some firms expressing confidence through upgrades and higher price targets, while others are more cautious.Mise à jour du récit • May 28
SDZ: Mixed Rating Shifts And Biosimilar Expansion Will Shape Future P/E
Analysts have adjusted the Sandoz Group price target slightly higher, with the updated fair value estimate moving from about CHF 66.01 to CHF 66.36 as they factor in modestly different assumptions for growth, margins and future P/E, following a mix of recent upgrades, initiations and target changes across the Street. Analyst Commentary Recent research on Sandoz Group reflects a mix of optimism and caution, with several firms adjusting ratings and price targets in different directions.Mise à jour du récit • May 01
SDZ: Mixed Rating Shifts And Biosimilar Deals Will Shape Future P/E
The updated analyst price target for Sandoz Group has been revised by approximately CHF 1 higher, reflecting modestly adjusted assumptions around fair value, revenue growth, profit margins and future P/E as analysts balance recent target changes and rating shifts across major banks. Analyst Commentary Recent Street research around Sandoz Group shows a mix of optimism on the company’s long term potential and caution on how current pricing and expectations line up with execution risks.Mise à jour du récit • Apr 16
SDZ: Elevated Expectations Will Test Execution On Biosimilar Expansion Plans
Analysts have raised the Sandoz Group price target by roughly CHF 2 per share, reflecting a higher assumed fair value. This is supported by a series of recent CHF 3 to CHF 9 target increases from major banks and generally constructive views, despite some rating downgrades.
Mise à jour du récit • Apr 01
SDZ: Future P/E Repricing And Biosimilar Expansion May Drive Re Rating
Analysts have lifted the price target for Sandoz Group from CHF 60.37 to CHF 81.99, citing recent initiations, upgrades and target increases that highlight a higher assumed future P/E multiple and slightly improved profit margin expectations, despite more measured revenue growth assumptions. Analyst Commentary Recent Street research on Sandoz Group presents a mixed picture, but there is a clear strand of optimism around execution, earnings quality and the scope for the shares to support higher valuation multiples.Mise à jour du récit • Mar 18
SDZ: Mixed Rating Shifts And Biosimilar Expansion Will Shape Future P/E
Analysts have lifted the Fair Value estimate for Sandoz Group from CHF 62.57 to CHF 65.45. This reflects a series of higher Street price targets around CHF 62 to CHF 75 and updated assumptions for modestly higher revenue growth, a slightly lower profit margin profile, and a higher future P/E multiple.Mise à jour du récit • Mar 04
SDZ: Mixed Rating Shifts And Biosimilar Pipeline Progress Will Shape Future P/E
Analysts have lifted their fair value estimate for Sandoz to about CHF 63, reflecting updated assumptions for slightly lower revenue growth, a higher profit margin and a modestly lower future P/E, along with recent mixed rating changes and higher price targets in the CHF 70 to CHF 75 range. Analyst Commentary Recent Street research on Sandoz shows a mix of optimism and caution, with price targets now clustering in the CHF 70 to CHF 75 range and ratings shifting closer to neutral.Mise à jour du récit • Feb 18
SDZ: Richer Future P/E Assumptions Will Test Biosimilar Execution Confidence
Our latest narrative update on Sandoz Group reflects a higher implied fair value of CHF 58.42, up from CHF 52.75, supported by recent analyst price target increases and a willingness to assign a richer future P/E multiple. Analyst Commentary Recent Street research around Sandoz Group has centered on a series of price target revisions and at least one rating upgrade, which together frame how the analyst community is thinking about valuation, execution risk, and growth potential.Mise à jour du récit • Feb 03
SDZ: Elevated Expectations Will Confront Ongoing Execution And Manufacturing Setbacks
Analysts have raised their average price target on Sandoz Group by CHF 3 to CHF 60, citing updated assumptions for revenue growth, profit margins and future P/E, in line with recent target increases from several major banks. Analyst Commentary Recent Street research on Sandoz Group has largely focused on recalibrating price targets to reflect updated views on revenue growth, profitability and valuation multiples.Mise à jour du récit • Jan 20
SDZ: Rising Biosimilar Pipeline Will Face Ongoing Execution And Manufacturing Risks
Narrative Update The updated analyst price target for Sandoz Group reflects a modestly lower fair value estimate alongside slightly higher revenue growth and profit margin assumptions. Recent Street research citing price target moves to CHF 60 and CHF 70 indicates that analysts see room for the shares to better reflect these revised expectations.Mise à jour du récit • Jan 06
SDZ: Elevated Biosimilar Ambitions Will Face Ongoing Execution And Manufacturing Risks
Analysts have lifted their average price targets on Sandoz Group into a CHF 49 to CHF 70 range, and our updated fair value of CHF 44.42 nudges slightly lower as higher assumed profit margins and revenue growth are offset by a reduced future P/E multiple. Analyst Commentary Recent Street research on Sandoz Group shows a cluster of higher price targets, with targets in the CHF 49 to CHF 70 range.Mise à jour du récit • Dec 21
SDZ: Elevated Expectations Will Face Execution Risks In Biosimilars Expansion
Sandoz Group's analyst price target has been lifted by roughly CHF 6.50 to around CHF 60, as analysts now factor in stronger revenue growth, modestly higher profit margins, and a richer forward valuation multiple. Analyst Commentary Recent Street research has been broadly constructive on Sandoz Group, with several major firms lifting their price targets into the CHF 49 to CHF 60 range and maintaining positive ratings.Mise à jour du récit • Dec 07
SDZ: Biosimilar Launch Execution Will Shape Future Multiple And Risk Balance
Sandoz Group’s analyst price target has been nudged higher, with fair value estimates rising by about CHF 1.10 to CHF 52.75 as analysts point to sustained revenue growth expectations and a modestly higher future P E multiple, despite slightly lower margin forecasts. Analyst Commentary Bullish analysts have recently raised their price targets into the CHF 55 to CHF 60 range, signaling growing confidence that Sandoz can sustain above market growth and support a higher valuation multiple.Mise à jour du récit • Nov 23
SDZ: Sustained Revenue Momentum And Margin Focus Will Shape Fair Value Ahead
The analyst consensus price target for Sandoz Group has increased to CHF 60 from CHF 55. Analysts cite improved margin outlook and sustained revenue growth as key factors supporting the upward revision.Mise à jour du récit • Nov 09
SDZ: Recent US Launch and European Expansion Will Influence Near-Term Performance
The average analyst price target for Sandoz Group has increased from CHF 50.33 to CHF 52.05, reflecting improved revenue growth forecasts and recent supportive analyst research updates. Analyst Commentary Recent analyst updates reflect a mix of optimism and caution regarding Sandoz Group's valuation, growth prospects, and execution.Mise à jour du récit • Oct 26
Future Opportunities Will Be Unlocked Through Expanding Pipeline And Global Market Reach
The analyst consensus price target for Sandoz Group rose modestly, increasing from CHF 50.20 to CHF 50.33. Analysts cited stronger revenue growth and improving profit margins in their updated outlooks.Mise à jour du récit • Oct 12
Biosimilar Pipeline And Global Expansion Will Unlock Future Opportunities
The analyst price target for Sandoz Group has increased by CHF 0.81. This reflects positive sentiment from analysts who cite strong revenue growth and continued profitability improvements as supporting factors.Nouveau récit • Aug 17
Biosimilar Pipeline And Global Expansion Will Unlock Future Opportunities
Key Takeaways Accelerated biosimilar launches, improved manufacturing, and strong market share are driving margin expansion and long-term profitability. Strategic focus on international growth and a robust product pipeline positions the company for sustainable earnings momentum.Rendement pour les actionnaires
| SDZ | CH Pharmaceuticals | CH Marché | |
|---|---|---|---|
| 7D | -3.0% | -0.3% | 0.6% |
| 1Y | 43.7% | 32.2% | 15.8% |
Rendement vs Industrie: SDZ a dépassé le secteur Swiss Pharmaceuticals qui a rapporté 32.2 % au cours de l'année écoulée.
Rendement vs marché: SDZ a dépassé le marché Swiss qui a rapporté 15.8 % au cours de l'année écoulée.
Volatilité des prix
| SDZ volatility | |
|---|---|
| SDZ Average Weekly Movement | 3.8% |
| Pharmaceuticals Industry Average Movement | 4.6% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in CH Market | 7.5% |
| 10% least volatile stocks in CH Market | 2.1% |
Cours de l'action stable: SDZ n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché Swiss.
Volatilité au fil du temps: La volatilité hebdomadaire de SDZ ( 4% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1886 | 22,356 | Richard Saynor | www.sandoz.com |
Sandoz Group AG développe, fabrique et commercialise des produits pharmaceutiques génériques et des biosimilaires dans le monde entier. L'entreprise couvre des domaines thérapeutiques tels que le cardiovasculaire, le système nerveux central, l'oncologie, les maladies infectieuses, la douleur et les voies respiratoires, le diabète, l'immunologie, l'endocrinologie, l'hématologie et l'ophtalmologie. Elle propose également un portefeuille d'ingrédients pharmaceutiques actifs et de formes de dosage finies.
Sandoz Group AG Résumé des fondamentaux
| SDZ statistiques fondamentales | |
|---|---|
| Capitalisation boursière | CHF 28.45b |
| Bénéfices(TTM) | CHF 737.83m |
| Recettes(TTM) | CHF 9.01b |
38.6x
Ratio P/E3.2x
Ratio P/SLe site SDZ est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| SDZ compte de résultat (TTM) | |
|---|---|
| Recettes | US$11.16b |
| Coût des recettes | US$5.86b |
| Marge brute | US$5.30b |
| Autres dépenses | US$4.39b |
| Les revenus | US$914.00m |
Derniers bénéfices déclarés
Dec 31, 2025
Prochaine date de publication des résultats
Aug 05, 2026
| Résultat par action (EPS) | 2.11 |
| Marge brute | 47.50% |
| Marge bénéficiaire nette | 8.19% |
| Ratio dettes/capitaux propres | 56.6% |
Quelles ont été les performances à long terme de SDZ?
Voir les performances historiques et les comparaisonsDividendes
1.2%
Rendement actuel des dividendes48%
Ratio de distributionAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/07/19 23:12 |
| Cours de l'action en fin de journée | 2026/07/17 00:00 |
| Les revenus | 2025/12/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Sandoz Group AG est couverte par 36 analystes. 14 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Emily Field | Barclays |
| James Gordon | Barclays |
| Sidhartha Modi | Barclays |